ScreenerHero

JANX Janux Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · januxrx.com
17.92USD+6.73%Mkt Cap: 1.10B $P/E: —

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.10B USD
Enterprise Value77.79M USD
Revenue (TTM)24.00M USD
Gross Profit-99.98M USD
Net Income (TTM)-113.63M USD
Revenue/Share0.38 USD
Last Price17.92 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees113
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.40
PEG—
EV/EBITDA-0.55
EV/Revenue3.24
P/S42.77
P/B1.11
EPS (TTM)-1.66
EPS (Forward)-2.62
52W Range
12.1225% of range35.34
52W High35.34 USD
52W Low12.12 USD
Profitability
Gross Margin0.00%
Oper. Margin-308.66%
EBITDA Margin0.00%
Profit Margin-1136.25%
ROE-11.88%
ROA-11.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-82.23M USD
CapEx (TTM)1.04M USD
FCF Margin-68.30%
FCF Yield-1.50%
Net Debt-949.92M USD
Net Debt/EBITDA6.71
Balance Sheet
Debt/Equity0.02
Current Ratio16.35
Quick Ratio16.25
Book Value/Sh15.19 USD
Cash/Share15.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.24 USD
Upside (mean)+102.2%
Target Range14.00 USD – 75.00 USD
14.00+102.2% to mean75.00
# Analysts17
Ownership
Shares Out.61.14M
Float42.53M
Insiders0.99%
Institutions101.35%
Short Interest
Short Ratio6.6d
Short % Float12.34%
Short % Out.9.64%
Shares Short5.89M
Short (prev mo.)6.63M
Technical
SMA 5017.11 (+4.8%)
SMA 20015.00 (+19.4%)
Beta2.39
S&P 52W Chg16.45%
Avg Vol (30d)924.84K
Avg Vol (10d)783.16K
Technical Indicators
RSI (14)56.4
MACD-0.0543
MACD Signal-0.0507
MACD Hist.-0.0036
BB Upper19.12 USD
BB Middle17.22 USD
BB Lower15.32 USD
BB Width22.07%
ATR (14)0.8455 USD
Vol Ratio (20d)1.36x